These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7527470)

  • 1. [Prostate specific antigen in patients with prostatic cancer--clinical usefulness of its measurement with sensitive enzyme immunoassay, TOSOH II PA assay].
    Shinka T; Miyai M; Sawada Y; Ohkawa T
    Nihon Hinyokika Gakkai Zasshi; 1994 Oct; 85(10):1494-501. PubMed ID: 7527470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of prostate-specific antigen measurements with newly developed enzyme immunoassay (MARKIT-M PA)].
    Arai Y; Onishi H; Oishi K; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1992 Oct; 38(10):1129-34. PubMed ID: 1282772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of various assay systems for prostate-specific antigen standardization.
    Kuriyama M; Akimoto S; Akaza H; Arai Y; Usami M; Imai K; Tanaka Y; Yamazaki H; Kawada Y; Koiso K
    Jpn J Clin Oncol; 1992 Dec; 22(6):393-9. PubMed ID: 1283993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
    Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
    J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
    Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
    Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Measurement of serum PA values by a newly developed enzyme immunoassay].
    Kuriyama M; Esaki N; Shinoda I; Ito S; Yamada S; Tokuyama K; Deguchi T; Takahashi Y; Kawada Y; Akimoto S
    Nihon Hinyokika Gakkai Zasshi; 1993 Feb; 84(2):244-50. PubMed ID: 7681886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay].
    Akino H; Tsuka H; Okada K; Tsuchiya Y; Matsubara M; Arimura K
    Hinyokika Kiyo; 1995 Jun; 41(6):439-45. PubMed ID: 7544063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Dec; 34(12):2143-8. PubMed ID: 2467543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer.
    Arai Y; Onishi H; Oishi K; Takeuchi H; Yoshida O
    Jpn J Clin Oncol; 1993 Apr; 23(2):110-5. PubMed ID: 7685834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of tandem PSA for the diagnosis and follow-up of prostate cancer].
    Okaneya T; Mizusawa H; Taguchi I; Yoneyama T
    Hinyokika Kiyo; 1996 Nov; 42(11):861-7. PubMed ID: 8973936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical evaluation of a new kit (IMX PA Dainapack) for detection of serum prostate specific antigen].
    Machida T; Ohishi Y; Wada T; Akimoto S; Shimazaki J; Oda H; Yokoyama M; Tsukada T; Nakayama T; Akiyama A
    Hinyokika Kiyo; 1993 Oct; 39(10):977-84. PubMed ID: 7505519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer.
    Chen YT; Luderer AA; Thiel RP; Carlson G; Cuny CL; Soriano TF
    Urology; 1996 Apr; 47(4):518-24. PubMed ID: 8638360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ratio of gamma-seminoprotein to prostate-specific antigen for the detection of prostate cancer: its discrimination power could be influenced by the assay methods of PSA and/or gamma-seminoprotein.
    Akino H; Suzuki Y; Oyama N; Kanamaru H; Okada K
    Int J Urol; 1999 Sep; 6(9):440-5. PubMed ID: 10510889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
    Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
    J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The periurethral glands do not significantly influence the serum prostate specific antigen concentration.
    Oesterling JE; Tekchandani AH; Martin SK; Bergstralh EJ; Reichstein E; Diamandis EP; Yemoto C; Stamey TA
    J Urol; 1996 May; 155(5):1658-60. PubMed ID: 8627847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Basic and clinical evaluation of the new kit for detection of serum prostate specific antigen (PSA)].
    Akiyama A; Tochimoto M; Ito T; Tsujino S; Aizawa T; Namiki K; Miki M
    Kaku Igaku; 1992 Sep; 29(9):1151-8. PubMed ID: 1280697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.